These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24485356)

  • 1. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.
    Matsumoto S; Shimabukuro M; Fukuda D; Soeki T; Yamakawa K; Masuzaki H; Sata M
    Cardiovasc Diabetol; 2014 Jan; 13():30. PubMed ID: 24485356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.).
    Barauna VG; Mantuan PR; Magalhães FC; Campos LC; Krieger JE
    Biochem Biophys Res Commun; 2013 Nov; 441(4):713-9. PubMed ID: 24211212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
    Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome.
    Kagota S; Maruyama-Fumoto K; Shimari M; McGuire JJ; Shinozuka K
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):501-509. PubMed ID: 31420755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice.
    Oak JH; Cai H
    Diabetes; 2007 Jan; 56(1):118-26. PubMed ID: 17192473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azilsartan, an angiotensin II type 1 receptor blocker, attenuates tert-butyl hydroperoxide-induced endothelial cell injury through inhibition of mitochondrial dysfunction and anti-inflammatory activity.
    Liu H; Mao P; Wang J; Wang T; Xie CH
    Neurochem Int; 2016 Mar; 94():48-56. PubMed ID: 26879328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress.
    Zhang H; Zhang J; Ungvari Z; Zhang C
    Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1164-71. PubMed ID: 19478208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser
    Cho DH
    J Korean Med Sci; 2019 Nov; 34(42):e266. PubMed ID: 31674157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
    Miura S; Okabe A; Matsuo Y; Karnik SS; Saku K
    Hypertens Res; 2013 Feb; 36(2):134-9. PubMed ID: 23034464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2.
    Li W; Wang C; Zhang D; Zeng K; Xiao S; Chen F; Luo J
    Aging (Albany NY); 2021 May; 13(9):12996-13005. PubMed ID: 33946046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.
    Pham PT; Fukuda D; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M
    Sci Rep; 2019 Aug; 9(1):11206. PubMed ID: 31371788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
    Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
    Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of I
    Luo Y; Zhang Q; Ding J; Yu M; Jiang J; Yang F; Wang S; Wang A; Wang L; Wu S; Xia Y; Lu D
    Biochem Biophys Res Commun; 2019 Aug; 516(3):613-618. PubMed ID: 31239152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na+-H+ Exchanger-3 in Mice.
    Hatanaka M; Kaimori JY; Yamamoto S; Matsui I; Hamano T; Takabatake Y; Ecelbarger CM; Takahara S; Isaka Y; Rakugi H
    PLoS One; 2016; 11(1):e0147786. PubMed ID: 26807585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A; Flierl U; Vogt C; Menninger S; Tas P; Ertl G; Bauersachs J
    Pharmacol Res; 2007 Sep; 56(3):217-23. PubMed ID: 17669665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.
    Youn JY; Gao L; Cai H
    Diabetologia; 2012 Jul; 55(7):2069-79. PubMed ID: 22549734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
    Nemoto S; Kobayashi T; Taguchi K; Matsumoto T; Kamata K
    Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2383-94. PubMed ID: 21926342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.
    Suehiro T; Tsuruya K; Yoshida H; Tsujikawa H; Yamada S; Tanaka S; Tsuchimoto A; Eriguchi M; Fujisaki K; Torisu K; Nakano T; Kitazono T
    Kidney Blood Press Res; 2021; 46(2):173-184. PubMed ID: 33677450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
    Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
    Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.